首页> 外文期刊>中华医学杂志(英文版) >Efficacy and Safety of Different Bisphosphonates for Bone Loss Prevention in Kidney Transplant Recipients: A Network Meta-Analysis of Randomized Controlled Trials
【24h】

Efficacy and Safety of Different Bisphosphonates for Bone Loss Prevention in Kidney Transplant Recipients: A Network Meta-Analysis of Randomized Controlled Trials

机译:预防肾脏移植受者骨丢失的双膦酸盐的疗效和安全性:随机对照试验的网络荟萃分析

获取原文
获取原文并翻译 | 示例
           

摘要

Background:Mineral and bone disorder is one of the severe complications in kidney transplant recipients (KTRs).Previous studies showed that bisphosphonates had favorable effects on bone mineral density (BMD).We sought to compare different bisphosphonate regimens and rank their strategies.Methods:We searched PubMed,Embase,and the Cochrane Central Register of Controlled Trials (CENTRAL) up to April 01,2017,for randomized controlled trials (RCTs) comparing bisphosphonate treatments in adult KTRs.The primary outcome was BMD change.We executed the tool recommended by the Cochrane Collaboration to evaluate the risk of bias.We performed pairwise meta-analyses using random effects models and network meta-analysis (NMA) using Bayesian models and assessed the quality of evidence.Results:A total of 21 RCTs (1332 participants) comparing 6 bisphosphonate regimens were included.All bisphosphonates showed a significantly increased percentage change in BMD at the lumbar spine compared to calcium except clodronate.Pamidronate with calcium and Vitamin D analogs showed improved BMD in comparison to clodronate with calcium (mean difference [MD],9.84;95% credibility interval [CrI],1.06-19.70).The combination of calcium and Vitamin D analogs had a significantly lower influence than adding either pamidronate or alendronate (MD,6.34;95% CrI,2.59-11.01 and MD,6.16;95% CrI,0.54-13.24,respectively).In terms of percentage BMD change at the femoral neck,both pamidronate and ibandronate combined with calcium demonstrated a remarkable gain compared with calcium (MD,7.02;95% CrI,0.30-13.29 and MD,7.30;95% CrI,0.32-14.22,respectively).The combination of ibandronate with calcium displayed a significant increase in absolute BMD compared to any other treatments and was ranked best.Conclusions:Our NMA suggested that new-generation bisphosphonates such as ibandronate were more favorable in KTRs to improve BMD.However,the conclusion should be treated with caution due to indirect comparisons.
机译:背景:矿物质和骨骼疾病是肾移植受者(KTR)的严重并发症之一,先前的研究表明双膦酸盐对骨矿物质密度(BMD)有良好的作用,我们试图比较不同的双膦酸盐治疗方案并对其策略进行排名。我们搜寻了截至2017年4月1日的PubMed,Embase和Cochrane对照试验中央登记册(CENTRAL),以比较成年KTR中双膦酸盐治疗的随机对照试验(RCT)。主要结果是BMD改变。我们执行了推荐的工具由Cochrane协作组织评估偏倚风险。我们使用随机效应模型进行了成对荟萃分析,并使用贝叶斯模型进行了网络荟萃分析(NMA),并评估了证据的质量。结果:共有21项RCT(1332名参与者)比较了6种双膦酸盐方案。与钙排泄物相比,所有双膦酸盐显示腰椎BMD的百分比变化显着增加帕米膦酸钠与钙和维生素D类似物的对比显示BMD优于含钙的氯膦酸盐(平均差[MD],9.84; 95%可信区间[CrI],1.06-19.70)。与添加帕米膦酸或阿仑膦酸盐相比,其影响显着更低(分别为MD,6.34; 95%CrI,2.59-11.01和MD,6.16; 95%CrI,0.54-13.24)。帕米膦酸和伊班膦酸盐与钙的组合比钙表现出显着的增加(MD,7.02; 95%CrI,0.30-13.29和MD,7.30; 95%CrI,0.32-14.22)。结论:我们的NMA建议新一代的双膦酸盐(如伊班膦酸盐)在KTR中更有利于改善BMD。但是,由于间接比较,应谨慎对待结论。

著录项

  • 来源
    《中华医学杂志(英文版)》 |2018年第7期|818-828|共11页
  • 作者单位

    Division of Nephrology, Kidney Research Institute, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;

    Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;

    Division of Nephrology, Kidney Research Institute, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;

    Division of Nephrology, Kidney Research Institute, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;

    Department of Neurology, Stroke Clinical Research Unit, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;

    Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;

    Division of Nephrology, Kidney Research Institute, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;

  • 收录信息 中国科学引文数据库(CSCD);中国科技论文与引文数据库(CSTPCD);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号